APA (7th ed.) Citation

Li, W., & Schmid-Bindert, G. (2014). T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung cancer, 84(3), . https://doi.org/10.1016/j.lungcan.2014.03.011

Chicago Style (17th ed.) Citation

Li, Wei, and Gerald Schmid-Bindert. "T790M Mutation Is Associated with Better Efficacy of Treatment Beyond Progression with EGFR-TKI in Advanced NSCLC Patients." Lung Cancer 84, no. 3 (2014). https://doi.org/10.1016/j.lungcan.2014.03.011.

MLA (9th ed.) Citation

Li, Wei, and Gerald Schmid-Bindert. "T790M Mutation Is Associated with Better Efficacy of Treatment Beyond Progression with EGFR-TKI in Advanced NSCLC Patients." Lung Cancer, vol. 84, no. 3, 2014, https://doi.org/10.1016/j.lungcan.2014.03.011.